In the activation of HPV-specific human B cells HPV-VLP vaccines mimic membrane-associated antigens
Abstract
B cell responses to membrane-presented antigens appear to be strongly favored over soluble antigens in vivo suggesting that vaccines that mimic membrane-presented antigens may be highly efficacious. We recently demonstrated that human B cell responses to membrane-associated but not to soluble antigens in vitro depended on the expression and activity of the plasma membrane mechanosensitive ion channel, Piezo1. Here, we provide evidence that the efficacy of the current human papillomavirus virus-like particle (HPV VLP) vaccines may be due in part to their inherent ability to mimic Piezo1-dependent membrane presentation of antigens to B cells. We compared HPV-specific human B cell responses to HPV VLPs versus soluble HPV pentameric capsomeres and showed that although both induced calcium responses, only HPV VLP-induced responses were blocked by Piezo1 inhibitors. The kinetics of internalization of HPV-VLP and capsomeres into HPV-specific B cells were similar and neither required Piezo1 function as shown by small interfering RNA (siRNA)-mediated knockdown of Piezo. However, trafficking of HPV-VLPs into intracellular major histocompatibility complex (MHC) class II, lysosomal associated membrane protein 1 (LAMP1) + antigen-processing compartments was Piezo1-dependent, whereas trafficking of capsomeres was not. In addition, a time course of intracellular trafficking suggested that colocalization of HPV-VLP with MHC classII was more stable over time as compared to capsomeres. Taken together these findings suggest that the ability of HPV-VLP vaccines to mimic Piezo1-dependent membrane antigen presentation may be exploited in the design of highly effective human vaccines.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (15)
Charles Torgbor
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Haewon Sohn
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Brian L. P. Dizon
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Evan C. Mutic
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Rachel George
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Kihyuck Kwak
Department of Microbiology and Immunology, Institute for Immunology and Immunological Diseases, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine
Munir Akkaya
Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University
Esin Bayrali Ulker
Division of Rheumatology and Immunology, Department of Internal Medicine, College of Medicine, The Ohio State University
Maria Traver
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Joseph Brzostowski
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH
Denise A. Galloway
Human Biology Division, Fred Hutchinson Cancer Research Center
Cynthia D. Thompson
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH
Nicolas Çuburu
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH
John T. Schiller
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, NIH
Susan K. Pierce
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, NIH